[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

Summary

This will be a pivotal prospective prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial to assess the diagnostic performance and safety of the positron emission tomography (PET) imaging agent \[68Ga\]Ga-PTF) , versus \[18F\]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma exemplary for CXCR4-positive malignant lymphomas.

Timeline

Start

2024-05-20

Primary completion

2025-07-18

Completion

2025-07-18

Drugs

Indications